Despite decades of bile acid research, diverse biological roles for bile acids have been
discovered recently due to developments in understanding the human microbiota. As …

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …

Background Primary biliary cholangitis is a rare, chronic cholestatic liver disease
characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver …

Background Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-
specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development …

Background The prognoses with respect to mortality and hepatic and nonhepatic outcomes
across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well …

Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

The multimodal activities of farnesoid X receptor (FXR) agonists make this class an attractive
option to treat nonalcoholic steatohepatitis. The safety and efficacy of tropifexor, an FXR …

Non-alcoholic fatty liver disease (NAFLD) is regarded as a pandemic that affects about a
quarter of the global population. Recently, host-gut microbiota metabolic interactions have …

Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions worldwide.
NAFLD and type 2 diabetes mellitus (T2DM) are known to frequently coexist and act …

Bile acids (BAs) can regulate their own metabolism and transport as well as other key
aspects of metabolic homeostasis via dedicated (nuclear and G protein-coupled) receptors …